Proceedings of the 2023 Viral Clearance Symposium, Session 2: Viral Clearance Strategy and Case Studies

References

1. 1.↵
   International Conference for Harmonisation. ICH Harmonised Tripartite Guideline Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin, Step 2, Draft version, Endorsed on 29 September 2022. ICH: Geneva, 2022.
2. 2.↵
   1. Xu L.,
   2. Lee S. B.,
   3. Fuchs C.,
   4. Hyams K. C.,
   5. Brorson K.,
   6. Swann P.

   Role of Risk Assessments in Viral Safety: An FDA Perspective. PDA J. Pharm. Sci. Technol. 2014, 68 (1), 6–10.

   OpenUrlFREE Full Text
3. 3.↵
   1. Ayuso E.,
   2. Mingozzi F.,
   3. Bosch F.

   Production, Purification and Characterization of Adeno-Associated Vectors. Curr. Gene Ther. 2010, 10 (6), 423–436.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Thorne B. A.,
   2. Quigley P.,
   3. Nichols G.,
   4. Moore C.,
   5. Pastor E.,
   6. Price D.,
   7. Ament J. W.,
   8. Takeya R. K.,
   9. Peluso R. W.

   Characterizing Clearance of Helper Adenovirus by a Clinical rAAV1 Manufacturing Process. Biologicals 2008, 36 (1), 7–18.

   OpenUrlPubMed
5. 5.↵
   1. Bennett A.,
   2. Patel S.,
   3. Mietzsch M.,
   4. Jose A.,
   5. Lins-Austin B.,
   6. Yu J. C.,
   7. Bothner B.,
   8. McKenna R.,
   9. Agbandje-McKenna M.

   Thermal Stability as a Determinant of AAV Serotype Identity. Mol. Ther. Methods Clin. Dev. 2017, 6, 171–182.

   OpenUrl